AstraZeneca (STU:ZEG) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:ZEG AstraZeneca PLC STU:ZEG
84 GF Score
Price €139.65
GF Value €155.81
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

STU:ZEG
84GF Score
AstraZeneca PLC STU:ZEG
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AstraZeneca (STU:ZEG) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of €139.65 is trading 10.4% below its estimated GF Value™ of €155.81. GuruFocus considers AstraZeneca to be Modestly Undervalued.

Key valuation signals for STU:ZEG:

  • Interest Expense (Positive):
  • GF Value™: €155.81 vs. price of €139.65 (10.4% below fair value)
  • GF Score™: 84/100 with 1 warning sign

No single metric tells the full story. See the STU:ZEG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
84GF Score

Get the complete analysis for STU:ZEG

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€139.65
Price
€155.81
GF Value